Crossmark Global Holdings Inc. Acquires 4,942 Shares of DaVita Inc. (NYSE:DVA)

Crossmark Global Holdings Inc. raised its holdings in DaVita Inc. (NYSE:DVA) by 19.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,769 shares of the company’s stock after buying an additional 4,942 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $4,601,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in DVA. Franklin Resources Inc. boosted its holdings in DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock valued at $8,885,000 after acquiring an additional 31,502 shares in the last quarter. FMR LLC boosted its stake in shares of DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares in the last quarter. Atom Investors LP bought a new stake in shares of DaVita during the 3rd quarter valued at about $4,094,000. Neo Ivy Capital Management purchased a new position in shares of DaVita during the third quarter valued at about $726,000. Finally, Assenagon Asset Management S.A. raised its stake in DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock worth $11,159,000 after buying an additional 49,885 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DVA shares. Barclays upped their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $161.80.

DaVita Stock Performance

Shares of DVA opened at $168.50 on Thursday. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock has a market cap of $13.82 billion, a P/E ratio of 18.18, a P/E/G ratio of 0.81 and a beta of 0.92. The business’s 50 day moving average price is $157.81 and its 200-day moving average price is $153.46. DaVita Inc. has a 52 week low of $103.40 and a 52 week high of $170.80.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the firm posted $2.85 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. Equities research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.